3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Independent reference data for 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid (CAS 775304-57-9), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene.M09 - Other drugs for disorders of the musculo-skeletal system

Synonyms and trade names

Ataluren; 775304-57-9; PTC124; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; Translarna; K16AME9I3V; Atalureno; DTXSID5046776; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DTXCID3026776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; atalurenum; RefChem:560297; M09AX03

Regulatory listings held on file

GHS notification summary	100% (2 / 2)

GHS hazard classification

GHS notification summary	100% (2 / 2)

This chemical does not meet GHS hazard criteria for 100% (2 of 2) of all reports.

Reported as not meeting GHS hazard criteria by 2 of 2 companies. For more detailed information, please visit ECHA C&L website.

What the public record says

3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid · CAS 775304-57-9 · C15H9FN2O3. UNII K16AME9I3V.

Source: PubChem / Wikidata; the batch COA governs where values differ.